News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novo Nordisk A/S to Restart Liraglutide Obesity Studies
June 23, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Novo Nordisk (NOVOb.CO) will re-launch late-stage trials of its new diabetes drug liraglutide for treating obesity, the company said on Tuesday in a vote of confidence in the drug that has overcome safety concerns.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Novo Nordisk
MORE ON THIS TOPIC
Lung cancer
AstraZeneca’s ATR Inhibitor Fails to Improve Survival in Phase III Lung Cancer Trial
December 22, 2025
·
1 min read
·
Annalee Armstrong
China
AstraZeneca Finds Another Jewel in China With up to $2B For KRAS Inhibitor
December 22, 2025
·
1 min read
·
Annalee Armstrong
Business
BioSpace
Editors’ Top 5 Biggest News Stories of the Year
December 22, 2025
·
10 min read
·
Annalee Armstrong
Infectious disease
Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study
December 19, 2025
·
2 min read
·
Tristan Manalac
